Praxis Precision Medicines, Inc. PRAX Business Segments
| FY'25 | FY'24 | ||
|---|---|---|---|
| Program-specific expenses by Product | |||
| Elsunersen | $6.83M+220% | $2.14M-85.4% | |
| Other early stage assets | $8.02M+73.0% | $4.63M-34.3% | |
| Relutrigine | $45.95M+633% | $6.27M+57.0% | |
| Ulixacaltamide | $63.21M-8.6% | $69.17M+255% | |
| Vormatrigine | $74.06M+303% | $18.36M+193% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Praxis Precision Medicines, Inc. break its business down?
- Praxis Precision Medicines, Inc. (PRAX) reports program-specific expenses by product across 5 parts — Elsunersen, Other early stage assets, Relutrigine, Ulixacaltamide and Vormatrigine. Each is extracted from the segment footnotes and tracked over time.
- Where does Praxis Precision Medicines, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Praxis Precision Medicines, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.